Birchview Capital, LP Travere Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $124 Million
- Q3 2025
A detailed history of Birchview Capital, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 43,060 shares of TVTX stock, worth $1.49 Million. This represents 0.83% of its overall portfolio holdings.
Number of Shares
43,060
Previous 103,000
58.19%
Holding current value
$1.49 Million
Previous $1.52 Million
32.48%
% of portfolio
0.83%
Previous 1.6%
Shares
11 transactions
Others Institutions Holding TVTX
# of Institutions
269Shares Held
100MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...